Ardelyx (ARDX) Shares Outstanding (2013 - 2026)
Ardelyx's (ARDX) quarterly Shares Outstanding (Entity) came in at $247.0 million in Q1 2026, up 3.25% YoY from $239.2 million in Q1 2025, and up 1.07% on a QoQ basis from $244.4 million in Q4 2025.
Ardelyx (ARDX) Shares Outstanding (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Shares Outstanding (Entity) data on file, last reported at $247.0 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 3.25% year-over-year to $247.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $247.0 million (up 3.25% YoY) and the FY2025 annual result came in at $244.4 million, up 2.66% from the prior year.
- Shares Outstanding (Entity) climbed to $247.0 million in Q1 2026, from $244.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $247.0 million in Q1 2026 to a low of $136.3 million in Q1 2022.
- A 5-year average of $217.2 million and a median of $234.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 75.51% — and 2024, when it grew 2.05%.
- Tracing ARDX's Shares Outstanding (Entity) over 5 years: stood at $158.7 million in 2022, then surged by 46.48% to $232.5 million in 2023, then advanced by 2.39% to $238.0 million in 2024, then increased by 2.66% to $244.4 million in 2025, then rose by 1.07% to $247.0 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $247.0 million (Q1 2026), $244.4 million (Q4 2025), and $243.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 248.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248.07 Mn |
| Mar 31, 2026 | 245.86 Mn |
| Dec 31, 2025 | 241.03 Mn |
| Sep 30, 2025 | 241.91 Mn |
| Jun 30, 2025 | 239.93 Mn |
| Mar 31, 2025 | 238.62 Mn |
| Dec 31, 2024 | 235.23 Mn |
| Sep 30, 2024 | 235.91 Mn |
| Jun 30, 2024 | 234.57 Mn |
| Mar 31, 2024 | 233.07 Mn |
| Dec 31, 2023 | 219.33 Mn |
| Sep 30, 2023 | 222.78 Mn |
| Jun 30, 2023 | 214.95 Mn |
| Mar 31, 2023 | 207.02 Mn |
| Dec 31, 2022 | 158.69 Mn |
| Sep 30, 2022 | 165.11 Mn |
| Jun 30, 2022 | 145.54 Mn |
| Mar 31, 2022 | 130.94 Mn |
| Dec 31, 2021 | 104.21 Mn |
| Sep 30, 2021 | 104.15 Mn |